Clinical Trial Update: Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating oral etoposide in combination with anlotinib for advanced triple negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Etoposide (oral) (etoposide)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN